Two Sigma Advisers
NPCE icon

Two Sigma Advisers’s Neuropace NPCE Stock Holding History

Two Sigma Advisers’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,100
Closed -$789K – 1424
2025
Q4 		$789K Buy
51,100
+13,000
+34% +$174K ﹤0.01% 1603
2025
Q3 		$393K Sell
38,100
-2,100
-5% -$19.8K ﹤0.01% 1867
2025
Q2 		$448K Buy
40,200
+19,300
+92% +$241K ﹤0.01% 1798
2025
Q1 		$257K Buy
20,900
+10,400
+99% +$130K ﹤0.01% 2048
2024
Q4 		$117K Buy
+10,500
New +$91.3K ﹤0.01% 2200

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Two Sigma Advisers's NPCE Position: Q1 2026 in Review

Two Sigma Advisers sold out of Neuropace (NPCE) in Q1 2026, closing a stake of 51,100 shares — an estimated $789K sold.

Two Sigma Advisers first reported a position in NPCE in Q4 2024 and held it in 5 quarters. The position peaked at $789K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Two Sigma Advisers reported no remaining Neuropace position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 51,100 Neuropace shares in Q1 2026, an estimated $789K.
  • Two Sigma Advisers first reported a position in Neuropace in Q4 2024 and held it in 5 quarters.
  • Two Sigma Advisers's Neuropace position peaked at $789K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.